drugset / Trial / NCT00728728

Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia

NCT00728728

Phase 2 Completed 88 enrolled VA Office of Research and Development
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will investigate adjunctive pregnenolone for patients with schizophrenia and schizoaffective disorder.

Timeline

Start
2009-12
Primary completion
2015-03
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pregnenolone Other / unclassified 250 mg